Anavex Life Sciences Reports Positive Results in Parkinson’s Disease Dementia Trial
Anavex Life Sciences has announced promising findings from the extension phase of its phase 2 study assessing ANAVEX2-73 (blarcamesine) for Parkinson’s disease dementia (PDD). The open-label extension (OLE) study spanned 48 weeks and demonstrated significant improvements in clinical symptoms among participants who resumed treatment. The trial faced an initial delay due to the COVID-19 pandemic, […]